Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527264 · ClinicalTrials.gov registry record · Phase 2
BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
A Phase 2 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03527264: Clinical Trial Phase 2 study, sponsored by Brown University.
NCT03527264 is a Phase 2 study that was terminated before completion, run by Brown University. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03527264, a Phase 2 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of the investigational drug in combination with radiation to learn whether the drug(s) works in treating a specific disease. In this study, researchers are studying three treatment arms, each using standard chemotherapy, with the drug cisplatin and radiation and the drug Nivolumab. Each treatment Arm will test the addition of Nivolumab at a different time point
Primary Outcome
Number of patients that are alive without disease progression at time of analysis.
Interventions
- DRUG Cisplatin
- RADIATION Radiation
- DRUG Nivolumab induction
- DRUG Nivolumab with chemoradiation
- DRUG Nivolumab maintenance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-11-08 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 2 |
Why NCT03527264 stopped before completion
NCT03527264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT03527264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03527264 about?
NCT03527264 is a clinical study titled "BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer". This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of the investigational drug in combination with radiation to learn whether the drug(s) works in treating a specific disease. In this study, researchers are studying three treatment arms, each...
What is the current status of trial NCT03527264?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-11-08. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT03527264?
The interventions under investigation include: Cisplatin (DRUG), Radiation (RADIATION), Nivolumab induction (DRUG), Nivolumab with chemoradiation (DRUG), Nivolumab maintenance (DRUG).
Who is sponsoring clinical trial NCT03527264?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03527264's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI